Loading clinical trials...
Loading clinical trials...
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Assess the Efficacy and Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialysis
Conditions
Interventions
Etelcalcetide
Placebo
Locations
106
United States
Research Site
Mobile, Alabama, United States
Research Site
Azusa, California, United States
Research Site
Beverly Hills, California, United States
Research Site
Chula Vista, California, United States
Research Site
Fairfield, California, United States
Research Site
Glendale, California, United States
Start Date
March 12, 2013
Primary Completion Date
April 14, 2014
Completion Date
May 9, 2014
Last Updated
August 20, 2019
NCT05382988
NCT01785875
NCT01922843
NCT00528788
Lead Sponsor
Amgen
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions